EIF5A
Basic information
Region (hg38): 17:7306999-7312463
Links
Phenotypes
GenCC
Source:
- Faundes-Banka syndrome (Strong), mode of inheritance: AD
- Faundes-Banka syndrome (Moderate), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Faundes-Banka syndrome | AD | Cardiovascular | Individuals may have congenital cardiovascular anomalies, and awareness may allow early identification and management | Cardiovascular; Craniofacial; Neurologic | 33547280 |
ClinVar
This is a list of variants' phenotypes submitted to
- Faundes-Banka syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the EIF5A gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 1 | |||||
missense | 6 | |||||
nonsense | 1 | |||||
start loss | 0 | |||||
frameshift | 3 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 1 | 1 | ||||
non coding | 1 | |||||
Total | 1 | 6 | 5 | 2 | 1 |
Variants in EIF5A
This is a list of pathogenic ClinVar variants found in the EIF5A region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
17-7307083-C-A | Likely benign (Jun 01, 2023) | |||
17-7307083-C-T | not specified | Uncertain significance (Oct 05, 2021) | ||
17-7307116-G-A | EIF5A-related disorder • Faundes-Banka syndrome | Uncertain significance (Mar 26, 2024) | ||
17-7309672-G-A | Faundes-Banka syndrome | Uncertain significance (Dec 06, 2023) | ||
17-7309712-G-C | Neurodevelopmental disorder | Likely pathogenic (Dec 21, 2020) | ||
17-7309759-G-A | Likely pathogenic (Sep 20, 2024) | |||
17-7309778-C-A | Faundes-Banka syndrome | Pathogenic (Jun 09, 2021) | ||
17-7309801-G-A | not specified | Likely pathogenic (Dec 18, 2023) | ||
17-7311008-A-G | Benign (Mar 03, 2015) | |||
17-7311041-CTT-C | Faundes-Banka syndrome | Likely pathogenic (Feb 03, 2023) | ||
17-7311089-G-A | Uncertain significance (Dec 07, 2023) | |||
17-7311123-G-A | Likely pathogenic (Mar 24, 2023) | |||
17-7311367-T-TG | EIF5A-related disorder | Uncertain significance (Jun 22, 2023) | ||
17-7311395-G-A | Pathogenic (Apr 24, 2024) | |||
17-7311402-T-TA | Faundes-Banka syndrome | Pathogenic (Jan 18, 2024) | ||
17-7311404-C-G | Faundes-Banka syndrome | Pathogenic (Jun 09, 2021) | ||
17-7311404-C-T | Faundes-Banka syndrome | Pathogenic (Dec 28, 2023) | ||
17-7311416-C-T | Uncertain significance (Oct 24, 2023) | |||
17-7311422-C-T | Likely pathogenic (Apr 03, 2023) | |||
17-7311422-CCT-C | Likely pathogenic (Apr 01, 2024) | |||
17-7311574-C-T | not specified | Likely benign (Nov 01, 2017) | ||
17-7311583-G-A | Likely benign (Oct 01, 2023) | |||
17-7311587-C-A | not specified | Uncertain significance (Jun 16, 2024) | ||
17-7311590-TC-AT | Faundes-Banka syndrome | Likely pathogenic (Apr 17, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
EIF5A | protein_coding | protein_coding | ENST00000336452 | 5 | 5457 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.737 | 0.261 | 125746 | 0 | 2 | 125748 | 0.00000795 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.41 | 35 | 104 | 0.336 | 0.00000601 | 1199 |
Missense in Polyphen | 0 | 20.38 | 0 | 266 | ||
Synonymous | -1.83 | 56 | 41.1 | 1.36 | 0.00000276 | 353 |
Loss of Function | 2.43 | 1 | 8.74 | 0.114 | 4.70e-7 | 112 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000579 | 0.0000579 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00 | 0.00 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: mRNA-binding protein involved in translation elongation. Has an important function at the level of mRNA turnover, probably acting downstream of decapping. Involved in actin dynamics and cell cycle progression, mRNA decay and probably in a pathway involved in stress response and maintenance of cell wall integrity. With syntenin SDCBP, functions as a regulator of p53/TP53 and p53/TP53-dependent apoptosis. Regulates also TNF- alpha-mediated apoptosis. Mediates effects of polyamines on neuronal process extension and survival. May play an important role in brain development and function, and in skeletal muscle stem cell differentiation. Also described as a cellular cofactor of human T-cell leukemia virus type I (HTLV-1) Rex protein and of human immunodeficiency virus type 1 (HIV-1) Rev protein, essential for mRNA export of retroviral transcripts. {ECO:0000269|PubMed:15371445, ECO:0000269|PubMed:15452064, ECO:0000269|PubMed:16987817, ECO:0000269|PubMed:17187778, ECO:0000269|PubMed:17360499}.;
- Pathway
- Translation Factors;eIF5A regulation in response to inhibition of the nuclear export system;Post-translational protein modification;Metabolism of proteins;Gamma carboxylation, hypusine formation and arylsulfatase activation;Hypusine synthesis from eIF5A-lysine
(Consensus)
Recessive Scores
- pRec
- 0.298
Intolerance Scores
- loftool
- 0.286
- rvis_EVS
- -0.05
- rvis_percentile_EVS
- 49.39
Haploinsufficiency Scores
- pHI
- hipred
- Y
- hipred_score
- 0.598
- ghis
- 0.632
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.996
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Low | Low |
Primary Immunodeficiency | Medium | Low | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Eif5a
- Phenotype
Gene ontology
- Biological process
- mRNA export from nucleus;translational frameshifting;protein export from nucleus;nucleocytoplasmic transport;apoptotic process;positive regulation of cytosolic calcium ion concentration;aging;positive regulation of cell population proliferation;positive regulation of cardiac muscle cell apoptotic process;negative regulation of apoptotic process;positive regulation of translational elongation;positive regulation of translational termination;positive regulation of muscle cell differentiation;cellular response to thyroid hormone stimulus;positive regulation of reactive oxygen species metabolic process
- Cellular component
- nucleus;annulate lamellae;nuclear pore;cytoplasm;endoplasmic reticulum membrane;cytosol;membrane;dendrite;neuronal cell body;synapse
- Molecular function
- RNA binding;translation elongation factor activity;protein binding;U6 snRNA binding;ribosome binding;protein N-terminus binding